• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2008 年至 2017 年期间,瑞典诊断时年龄在 40-74 岁的女性中,筛查检出和非筛查检出乳腺癌在肿瘤特征方面的年龄特异性差异。

Age-specific differences in tumour characteristics between screen-detected and non-screen-detected breast cancers in women aged 40-74 at diagnosis in Sweden from 2008 to 2017.

机构信息

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.

出版信息

J Med Screen. 2024 Dec;31(4):248-257. doi: 10.1177/09691413241237616. Epub 2024 Mar 7.

DOI:10.1177/09691413241237616
PMID:38454634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11526418/
Abstract

OBJECTIVE

To analyze differences between screen-detected and non-screen-detected invasive breast cancers by tumour characteristics and age at diagnosis in the nationwide population-based mammography screening program in Sweden.

METHODS

Data were retrieved from the National Quality Register for Breast Cancer for 2008-2017. Logistic regression analysis was used to estimate the likelihood for a tumour to be screen-detected by tumour characteristics and age group at diagnosis.

RESULTS

In total there were 51,429 invasive breast cancers in the target age group for mammography screening of 40-74 years. Likelihood of screen detection decreased with larger tumour size, lymph node metastases, higher histological grade and distant metastasis. Odds ratios (ORs) for negative oestrogen (ER) and progesterone (PgR) were 0.41 and 0.57; for positive HER2, 0.62; for Ki-67 high versus low, 0.49. Molecular sub-types had OR of 0.56, 0.40 and 0.28, respectively, for luminal B-like, HER2-positive and triple negative versus luminal A-like. Adjusting for tumour size (T), lymph node status (N), age, year and county at diagnosis slightly elevated the ORs. Statistically significant interactions between tumour characteristics and age were found ( < 0.05) except for ER and PgR. The age group 40-49 deviated most from the other age groups.

CONCLUSIONS

Our study demonstrates that screen-detected invasive breast cancers had more favourable tumour characteristics than non-screen-detected after adjusting for age, year and county of diagnosis, and even after adjusting for T and N. The trend towards favourable tumour characteristics was less pronounced in the 40-49 age group compared to the other age groups, except for ER and PgR.

摘要

目的

分析瑞典全国基于人群的乳腺 X 线筛查项目中,通过肿瘤特征和诊断时年龄对筛查检出与非筛查检出的浸润性乳腺癌之间的差异。

方法

数据来自 2008-2017 年全国乳腺癌质量登记处。采用逻辑回归分析估计肿瘤特征和诊断时年龄组对肿瘤筛查检出的可能性。

结果

在 40-74 岁的乳腺 X 线筛查目标年龄组中,共有 51429 例浸润性乳腺癌。随着肿瘤大小、淋巴结转移、组织学分级和远处转移的增加,筛查检出的可能性降低。阴性雌激素受体(ER)和孕激素受体(PgR)的比值比(OR)为 0.41 和 0.57;HER2 阳性的 OR 为 0.62;Ki-67 高表达与低表达的 OR 为 0.49。分子亚型的 OR 分别为 luminal B 样、HER2 阳性和三阴性相对于 luminal A 样的 0.56、0.40 和 0.28。调整肿瘤大小(T)、淋巴结状态(N)、年龄、诊断年份和诊断县后,OR 略有升高。除 ER 和 PgR 外,还发现肿瘤特征与年龄之间存在统计学显著的交互作用(<0.05)。40-49 岁年龄组与其他年龄组差异最大。

结论

我们的研究表明,在调整诊断时的年龄、年份和县以及甚至调整 T 和 N 后,筛查检出的浸润性乳腺癌比非筛查检出的具有更有利的肿瘤特征。与其他年龄组相比,40-49 岁年龄组的肿瘤特征趋势不太明显,除 ER 和 PgR 外。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d0/11526418/4e25d22b83d7/10.1177_09691413241237616-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d0/11526418/4e25d22b83d7/10.1177_09691413241237616-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52d0/11526418/4e25d22b83d7/10.1177_09691413241237616-fig1.jpg

相似文献

1
Age-specific differences in tumour characteristics between screen-detected and non-screen-detected breast cancers in women aged 40-74 at diagnosis in Sweden from 2008 to 2017.2008 年至 2017 年期间,瑞典诊断时年龄在 40-74 岁的女性中,筛查检出和非筛查检出乳腺癌在肿瘤特征方面的年龄特异性差异。
J Med Screen. 2024 Dec;31(4):248-257. doi: 10.1177/09691413241237616. Epub 2024 Mar 7.
2
Age-specific differences in breast cancer treatment between screen-detected and non-screen-detected breast cancers in women aged 40-74 years at diagnosis in Sweden 2008-2017.2008-2017 年瑞典诊断时年龄为 40-74 岁的女性中,筛查检出与非筛查检出乳腺癌在治疗上的年龄特异性差异。
Acta Oncol. 2024 Jul 5;63:552-556. doi: 10.2340/1651-226X.2024.40200.
3
Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.筛查检出浸润性乳腺癌与症状性浸润性乳腺癌亚型分布的差异及其对生存的影响。
Clin Transl Oncol. 2017 Oct;19(10):1232-1240. doi: 10.1007/s12094-017-1660-z. Epub 2017 Apr 13.
4
Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients.原发性浸润性乳腺癌前哨淋巴结转移的预测因素:2552 例连续患者的基于人群队列研究。
World J Surg Oncol. 2018 Mar 12;16(1):54. doi: 10.1186/s12957-018-1353-2.
5
Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.基于孕激素受体阴性状态新定义的雌激素受体阳性/孕激素受体阴性/人表皮生长因子受体2阴性乳腺癌的临床病理特征:一项来自中国的大型人群研究
PLoS One. 2015 May 4;10(5):e0125067. doi: 10.1371/journal.pone.0125067. eCollection 2015.
6
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.除了根据2013年圣加仑会议定义的乳腺癌亚型外,组织学分级还提供了重要的预后信息。
Acta Oncol. 2017 Jan;56(1):68-74. doi: 10.1080/0284186X.2016.1237778. Epub 2016 Oct 20.
7
Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing.人表皮生长因子受体 2(HER2)阳性乳腺癌的特征,这些乳腺癌是在普遍开展 HER2 检测之后诊断出来的。
Breast. 2012 Dec;21(6):724-9. doi: 10.1016/j.breast.2012.09.001. Epub 2012 Oct 23.
8
Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal.葡萄牙北部一项筛查计划中诊断出的间期癌和筛查发现的乳腺癌之间的临床病理差异。
J Med Screen. 2014 Jun;21(2):104-9. doi: 10.1177/0969141314534406. Epub 2014 May 6.
9
Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms.超声筛查阴性的女性中乳腺癌的超声特征。
Cancer Sci. 2011 Oct;102(10):1862-7. doi: 10.1111/j.1349-7006.2011.02034.x. Epub 2011 Aug 10.
10
Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain.不同类型间期癌的肿瘤表型和乳腺密度:西班牙基于人群的乳腺钼靶筛查结果
Breast Cancer Res. 2014 Jan 10;16(1):R3. doi: 10.1186/bcr3595.

引用本文的文献

1
Age-specific differences in breast cancer treatment between screen-detected and non-screen-detected breast cancers in women aged 40-74 years at diagnosis in Sweden 2008-2017.2008-2017 年瑞典诊断时年龄为 40-74 岁的女性中,筛查检出与非筛查检出乳腺癌在治疗上的年龄特异性差异。
Acta Oncol. 2024 Jul 5;63:552-556. doi: 10.2340/1651-226X.2024.40200.

本文引用的文献

1
Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers.与筛查检出的乳腺癌相比,间隔期乳腺癌的发病情况、特征和结局。
JAMA Netw Open. 2020 Sep 1;3(9):e2018179. doi: 10.1001/jamanetworkopen.2020.18179.
2
Effectiveness of Population-Based Service Screening with Mammography for Women Aged 70-74 Years in Sweden.瑞典针对70 - 74岁女性开展的基于人群的乳腺钼靶筛查服务的有效性。
Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2149-2156. doi: 10.1158/1055-9965.EPI-20-0523. Epub 2020 Aug 20.
3
Molecular comparison of interval and screen-detected breast cancers.
间期和筛查性乳腺癌的分子比较。
J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.
4
Breast cancer subtype and screening sensitivity in the Quebec Mammography Screening Program.魁北克乳房X光筛查项目中的乳腺癌亚型与筛查敏感性
J Med Screen. 2019 Sep;26(3):154-161. doi: 10.1177/0969141318816736. Epub 2018 Dec 20.
5
Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.基于人群的乳腺癌筛查计划中过度诊断的估计:使用具有长期随访的个体数据的非同质多状态模型的队列研究。
Breast Cancer Res. 2018 Dec 17;20(1):153. doi: 10.1186/s13058-018-1082-z.
6
Molecular subtypes of screen-detected breast cancer.筛查发现的乳腺癌的分子亚型。
Breast Cancer Res Treat. 2018 Nov;172(1):191-199. doi: 10.1007/s10549-018-4899-3. Epub 2018 Jul 25.
7
Breast cancer mortality and screening mammography in New Zealand: Incidence-based and aggregate analyses.新西兰的乳腺癌死亡率和筛查性乳房 X 光造影术:基于发病率的综合分析。
J Med Screen. 2019 Mar;26(1):35-43. doi: 10.1177/0969141318776039. Epub 2018 Jun 12.
8
Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.筛查检出浸润性乳腺癌与症状性浸润性乳腺癌亚型分布的差异及其对生存的影响。
Clin Transl Oncol. 2017 Oct;19(10):1232-1240. doi: 10.1007/s12094-017-1660-z. Epub 2017 Apr 13.
9
Mode of detection: an independent prognostic factor for women with breast cancer.检测方式:乳腺癌女性患者的一个独立预后因素。
J Med Screen. 2016 Jun;23(2):89-97. doi: 10.1177/0969141315604006. Epub 2015 Nov 17.
10
The benefits and harms of breast cancer screening: an independent review.乳腺癌筛查的获益与危害:一项独立评审。
Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0. Epub 2012 Oct 30.